Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy

Authors

Colin Shapiro

Published

November 1, 2024

Abstract

Supporters

Support the authors with ResearchCoin

Journal

Maturitas

Topics

Endocrinology, Diabetes And Metabolism

DOI

10.1016/j.maturitas.2024.108159

License

CC-BY

Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy

Authors

Colin Shapiro

Published

November 1, 2024

Abstract

Supporters

Support the authors with ResearchCoin

Journal

Maturitas

Topics

Endocrinology, Diabetes And Metabolism

DOI

10.1016/j.maturitas.2024.108159

License

CC-BY

Paper

Paper

Paper

Paper

Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy

Abstract

Supporters

Journal

Topics

DOI

License

Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy

Abstract

Supporters

Journal

Topics

DOI

License

Supporters

Journal

Topics

DOI

License